Institutional shares held 987 Million
7.62M calls
2.97M puts
Total value of holdings $10.4B
$80.4M calls
$31.3M puts
Market Cap $12.8B
1,212,669,952 Shares Out.
Institutional ownership 81.35%
# of Institutions 1,128


Latest Institutional Activity in VTRS

Top Purchases

Q2 2025
Rubric Capital Management LP Shares Held: 12M ($127M)
Q2 2025
Norges Bank Shares Held: 11.5M ($122M)
Q2 2025
Dimensional Fund Advisors LP Shares Held: 31.3M ($330M)
Q2 2025
Arrowstreet Capital, Limited Partnership Shares Held: 7.53M ($79.4M)
Q2 2025
D. E. Shaw & Co., Inc. Shares Held: 4.67M ($49.2M)

Top Sells

Q2 2025
State Street Corp Shares Held: 55.3M ($583M)
Q2 2025
Camber Capital Management LP Shares Held: 2.75M ($29M)
Q2 2025
Deutsche Bank Ag\ Shares Held: 5.44M ($57.4M)
Q2 2025
Schroder Investment Management Group Shares Held: 2.82M ($29.8M)
Q2 2025
Grantham, Mayo, Van Otterloo & Co. LLC Shares Held: 445K ($4.7M)

About VTRS

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.


Insider Transactions at VTRS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
2.09M Shares
From 17 Insiders
Exercise of conversion of derivative security 2M shares
Open market or private purchase 82K shares
Sell / Disposition
1.01M Shares
From 9 Insiders
Payment of exercise price or tax liability 782K shares
Open market or private sale 227K shares

Track Institutional and Insider Activities on VTRS

Follow Viatris Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VTRS shares.

Notify only if

Insider Trading

Get notified when an Viatris Inc insider buys or sells VTRS shares.

Notify only if

News

Receive news related to Viatris Inc

Track Activities on VTRS